GSK Trading Sluggish on Avandia Saga

Around ASCO time GSK was a promising stock being touted by life science investors as one of those undervalued stock that you can go both long and short. Even with the Avandia scandal going on, you’d think that GSK is almost invincible. Except it isn’t. Headlines around Avandia still dominates investor consciousness and even though [...]
Source: NAKEDMEDICINE.COM - Category: Health Medicine and Bioethics Commentators Authors: Tags: Science and Research Source Type: blogs